Biocytogen
Dr. James Jin received his PhD of virology at Wuhan University in 1997. He had his postdoctoral training at Colorado State University. He worked as a research assistant professor in University of Illinois at Chicago from 2005 to 2010. In 2010, he was recruited to Advanced Cell Technology, Inc. as a senior scientist. Dr. Jin joined Biocytogen as the director of technology in 2011, and then was promoted to vice president in 2012. His research covers virology, immunology, proteomics, protein structure, human stem cell, and gene-targeting animal model.
This person is not in any offices
Biocytogen
2 followers
Biocytogen is a preclinical stage biotech that provides a one-stop solution for antibody discovery from target to IND application. With cutting-edge technologies, state-of-art animal facility, and world-class platforms for antibody drug discovery, Biocytogen offers animal model generation, antibody fully human-mouse (RenMab mouse), therapeutic antibody discovery and development, in vivo/in vitro preclinical studies, CMC/CDMO, and regulatory affairs support.